Cross-Sector entity
Abbott Laboratories is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. acquisition accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. FreeStyle Libre appears in 2 tracked Cross-Sector stories from July 17, 2026.
2 verified stories tracked
Last mentioned: Jul 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Abbott Laboratories is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. acquisition accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. FreeStyle Libre appears in 2 tracked Cross-Sector stories from July 17, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering FreeStyle Libre. Shared-story counts are live from our verified record — not editorial picks.
Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.
Abbott’s newly acquired oncology diagnostics from Exact Sciences—Cologuard and Oncotype DX—are offsetting COVID testing declines and powering a Q2 earnings beat. The company lifted its full-year 2026 adjusted EPS target, highlighting the value of high-margin, recurring precision testing businesses.
Source: businesstimes.com.sg · health.economictimes.indiatimes.com
